Sanofi India is currently trading at Rs. 2261.00, up by 40.10 points or 1.81% from its previous closing of Rs. 2220.90 on the BSE.
The scrip opened at Rs. 2241.00 and has touched a high and low of Rs. 2261.00 and Rs. 2241.00 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2450.00 on 31-Jan-2013 and a 52 week low of Rs. 2002.10 on 07-Jun-2012.
Last one week high and low of the scrip stood at Rs. 2317.95 and Rs. 2210.00 respectively. The current market cap of the company is Rs. 5090.00 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 27.37% and 12.23% respectively.
Sanofi India has launched Combiflam Plus, a targeted, fast and effective solution for headaches, which is also gentle on the stomach. Combiflam Plus is a combination of paracetamol and caffeine which is a targeted solution for headaches. A line extension of one of Sanofi India’s flagship brands Combiflam, the launch of this new product marks the company’s foray into the OTC headache segment in India.
This combination has 89% incremental analgesic effect in terms of total pain relief when compared with paracetamol monotherapy. Further Caffeine has been shown to have a synergistic and well documented adjuvant action when combined with analgesics (painkillers). Research shows that adding caffeine to an analgesic for e.g. paracetamol increases the potency of the analgesic by approximately 40%.
In a first of its kind ‘Pack of 4s’ packaging in the headache category, Combiflam Plus is priced at Rs 9.50 (MRP) and will be available in the states of Uttar Pradesh, Maharashtra, Tamil Nadu, West Bengal, Punjab and Haryana.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1620.20 |
| Dr. Reddys Lab | 1316.15 |
| Cipla | 1294.10 |
| Zydus Lifesciences | 927.80 |
| Lupin | 2295.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: